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Abstract 
Background: Clinical trials suggest that use of fixed-dose combination therapy 
(‘polypills’) can improve adherence to medication and control of risk factors of people 
at high risk of cardiovascular disease (CVD) compared to usual care, but cost-
effectiveness is unknown.  
Objective: To determine whether a polypill is cost-effective compared to usual 
care and optimal guideline-recommended treatment for primary prevention in people 
already on statins and/or blood pressure lowering therapy.  
Methods: A Markov model was developed to perform a cost-utility analysis with a 
one year time cycle and a 10 year time horizon to compare the polypill with usual 
care and optimal implementation of NICE Guidelines, using patient level data from a 
retrospective cross-sectional study. The model was run for ten age (40 years+) and 
gender-specific sub-groups on treatment for raised CVD risk with no history of CVD. 
Published sources were used to estimate impact of different treatment strategies on 
risk of CVD events. 
Results: A polypill strategy was potentially cost-effective compared to other 
strategies for most sub-groups ranging from dominance to up to £18,811 per QALY 
depending on patient sub-group. Optimal implementation of guidelines was most 
cost-effective for women aged 40-49 and men aged 75+. Results were sensitive to 
polypill cost, and if the annual cost was less than £150, this approach was cost-
effective compared to the other strategies. 
Conclusions:  
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For most people already on treatment to modify CVD risk, a polypill strategy may be 
cost-effective compared with optimising treatment as per guidelines or their current 
care, as long as the polypill cost is sufficiently low.  
.   
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Introduction 
Poor uptake of pharmacotherapy for people at high risk of cardiovascular disease, 
and lack of adherence in people who are prescribed drugs, has generated interest in 
the potential for fixed dose combination pills (‘polypills’).[1,2] These can bring about 
important reductions in blood pressure and LDL cholesterol,[3] and are associated 
with improved adherence to therapy.[4,5,6,7] However, despite evidence from trials 
demonstrating that polypills are largely safe and effective, [8] availability still remains 
limited compared with other disease areas [9]. Furthermore, no polypill for prevention 
of cardiovascular disease is currently licensed for use in the United Kingdom.  
Previous cost-effectiveness analyses of polypills have primarily been concerned with 
treatment of secondary prevention patients [10,11], or, in primary prevention, 
comparing their use to no treatment, rather than to usual care or improved 
implementation of guidelines.[12,13] The aim of this study was to estimate the cost-
effectiveness of a polypill strategy compared with current treatment or treatment as 
per guidelines for primary prevention for patients with known high cardiovascular risk 
who are already prescribed statins and/or blood pressure lowering therapy. 
 
Methods 
A Markov cohort model developed in TreeAge Pro estimated cost-effectiveness of 
primary prevention with a polypill strategy compared with i) current therapy and ii) 
optimal therapy as per guidelines. The model considered patients aged 40 and over 
prescribed a statin and / or blood pressure lowering therapy with no history of 
cardiovascular disease. The model was run over a ten year time horizon with a one 
year cycle.  
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All patients started healthy and moved to other health states if they suffered stroke, 
myocardial infarction (MI), angina, heart failure or peripheral vascular disease (PVD) 
or died. Once a cardiovascular event occurred, they either died, or remained in this 
health state and incurred costs and a reduction in quality of life as assigned to that 
disease state until death (Fig 1).  
Fig 1 Model health states 
 
Study population 
A cross sectional retrospective study of primary care medical records in 19 West 
Midland general practices in England provided data on risk factor profiles and current 
treatment.[14]  Ten year cardiovascular risk was calculated using an updated 
Framingham equation.[15,16] The dataset was subdivided into ten age/gender 
subgroups (40-49, 50-59, 60-69, 70-74, 75 and over). Within each sub-group, eight 
treatment/cardiovascular risk strata were identified (S1 Table) that would be treated 
differently according to UK National Institute for Health and Care Excellence (NICE) 
guidelines.[17,18]   
Treatment strategies  
Current treatment for each stratum was characterised by whether a statin was being 
taken, and if antihypertensives were being taken, the average number per strata.  
The polypill strategy consisted of a pill a day containing a statin (40mg simvastatin) 
and three antihypertensives at half-dose (12.5mg hydrochlorothiazide, 5mg lisinopril, 
2.5mg amlodipine).[19]  As the patients were already taking medication, it was 
assumed the majority would take the polypill, with 16% discontinuing it (and 
therefore no longer incurring the cost of the polypill) and returning to their original 
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treatment.[20] The polypill strategy was applied regardless of baseline 
cardiovascular risk or systolic blood pressure. 
The guideline strategy assumed optimal treatment as per UK NICE guidelines.[17, 
18] Statin therapy (simvastatin 40mg) was prescribed if cardiovascular risk was 20% 
or higher, and antihypertensives if blood pressure was greater than 140/90mm/Hg 
and cardiovascular risk was 20% or greater.[17] In those patients already on 
antihypertensives, it was assumed that additional drugs would be added in order to 
reach a target systolic blood pressure of 140mmHg, up to a maximum of three drugs. 
We estimated the additional number of antihypertensive drugs that would be 
required using the results of a meta-analysis.[21] For each subgroup we used the 
starting systolic blood pressure and the degree of blood pressure lowering required 
to determine through linear interpolation how many additional drugs would be 
needed.  
Impact of treatment 
The baseline calculated 10 year cardiovascular risk was assumed to reflect benefit of 
current treatment (S1 Table), since the values of blood pressure and cholesterol in 
these patients reflected their current use of blood pressure lowering and lipid 
lowering drugs. For optimal guideline care, the impact of additional treatments was 
based on results of meta-analysis of randomised controlled trials (Table 1).[21, 22] 
We assumed 85% of people prescribed statins were fully compliant in taking their 
medication.[23]  For the polypill strategy, treatment already being received was taken 
into account. If already on statins, then no additional effect from statins was applied. 
If antihypertensives were already being taken, the baseline systolic blood pressure 
and average number of drugs taken was used to determine the amount of BP 
lowering already being achieved, and what effect switching to three half dose drugs 
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would have.[21] If switching to the polypill resulted in a lower dose of 
antihypertensives than current practice, risk estimates were adjusted accordingly. 
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Table 1 Summary of Model inputs 
 Data Sources 
Baseline mortality and risk of cardiovascular disease 
Probability of stroke (10 
years) 
0.7-6.2%(age and sex 
dependent) 
Calculated with Framingham 
[15,16]  and risk factor profile 
based on patient level data Probability of MI (10 years) 1.1-9.4% (age and sex 
dependent) 
Probability of angina (10 
years) 
1.5-13.3%(age and sex 
dependent) 
Probability of heart failure (10 
years) 
0.4-3.9%(age and sex 
dependent) 
Probability of PVD (10 years) 0.7-6.2% %(age and sex 
dependent) 
Assumed distribution of possible CV events within 10 year CV risk 
Stroke 16% D’Agostino (2008) [16] Wood 
(2004)
 
[24]  Myocardial infarction 24% 
Angina 34% 
Heart failure 10% 
PVD 16% 
   
Risk reduction with statins 
Stroke 0.80 (95% CI 0.73-0.86) CTT (2005),[22]
 
HPS 
(2002)[23]  
MI, HF, angina 0.72 (95% CI 0.69-0.76) CTT (2005), HPS (2002) 
PVD 0.85 (95% CI 0.75-0.95) HPS (2002) 
Probability of death from event 
Fatal stroke 0.19 Ward (2007)[25] 
Fatal MI 0.19-0.36 (Men) Ward (2007) 
 0.23-0.40 (Women)  
Fatal heart failure 0.17 (r=68, n=396) Mehta (2009) [26] 
SMR after stroke 2.72 (95% CI 2.59-2.85) Bronnum-Hansen (2001) [27] 
SMR after MI 2.68 (95% CI 2.48-2.91) Bronnum-Hansen (2001) [28] 
SMR after Heart Failure 2.17 (95% CI 1.96-2.41) de Guili (2005) [29] 
SMR after Angina 2.19 (95% CI 2.05-2.33) NCGC [30] 
SMR after PVD 2.44 (95% CI 1.59-3.74) Leng (1996) [31] 
Reduction in blood pressure 
Number of AHT drugs 
required to achieve target BP 
0.60-1.52  Law (2009)[21]  
Reduction in CV risk with reduction in BP 
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Polypill   
CHD risk 10-52% Law (2009) 
Stroke risk 14-65% Law (2009) 
PVD risk 13-23% Murabito (1997)[32] 
 (Dependent on age, sex and risk 
group) 
 
Treat to target   
CHD risk 15-37% Law (2009) 
Stroke risk 20-47% Law (2009) 
PVD risk 13-32% Murabito (1997) 
 (Dependent on age, sex and risk 
group) 
 
Polypill adherence 84% TIPS (2009)[20]  
 
Utilities   
No cardiovascular event (age and sex dependent) General population utilities 
from EQ-5D (UK Tariff) (NCSR, 
2006)[33] 
Death 0 By definition 
Quality of life multipliers   
Acute MI 0.76 (0.018) Cooper (2008)[18], NICE 
(2014) [34] 
Post MI 0.88 (0.018) As above 
Acute angina  0.77 (0.038) As above 
Post-acute angina 0.88 (0.018) As above 
Heart failure 0.68 (0.020) As above 
Stroke 0.63 (0.040) As above 
PVD 0.90 (0.020) As above 
Costs   
   
 £ per year  
Simvastatin 40mg 15.26 BNF March 2013 [35] 
Amlodopine 5mg 12.13 BNF March 2013 
Indapamide 2.5mg 11.87 BNF March 2013 
Ramipril 5mg 18.13 BNF March 2013 
Polypill 171 Assumed same price as 
Trinomia 
   
 Unit cost  £  
Blood test 15 Ward (2007) 
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GP visit 33 Curtis (2012) [36] 
Practice nurse visit 11.25 Curtis (2012) 
   
Acute events: One-off cost £  
Stroke 11,020 Youman (2003) [37} 
MI 5,487 Palmer (2002) [38] 
Angina 3,292 Assumed 60% of MI cost 
PVD 1,971 NHS Reference costs 2011/12 
[39] 
Heart failure 2,699 NHS Reference costs 2011/12  
   
Long-term costs £ per year  
Stroke 2721 Youman (2003) 
MI 572 Cooper (2008) [18] 
Angina 572 Cooper (2008) 
PVD 302 Cooper (2008) 
Heart failure 572 Cooper (2008) 
 
SMR: Standardised Mortality Ratio; MI: Myocardial infarction; PVD: Peripheral Vascular Disease; CV: 
Cardiovascular 
 
 
 
Outcomes 
Outcomes were measured in cardiovascular events and quality-adjusted life years 
(QALYs). A baseline utility value was applied depending upon age and gender.[33] 
When a cardiovascular event occurred, the health state value for that event was 
applied as a multiplier (Table 1). For consistency with other model-based analyses, 
utility values for CVD health states were obtained from previous UK NICE guidelines, 
where values were obtained through systematic review [18,34]. No reduction in 
quality of life was assumed for any drugs.[40] 
Gender-specific life tables were used to determine the probability of death at 
different ages.[41] The risk of death was adjusted to ensure there was no double 
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counting of cardiovascular death.[42] There was an increased risk of death once in a 
cardiovascular event health state. 
 
 
Costs 
Costs assumed a UK NHS and personal social services perspective (Table 1). 
Polypill costs comprised: £171 (€192) a year for the pill, an initial GP visit and blood 
test in the first month, and an annual practice nurse visit and blood test thereafter. 
Due to the absence of a UK cost for a polypill, the cost was assumed to be in line 
that of an existing secondary prevention polypill (Trinomia®), which has a different 
composition. The cost was calculated using the mean of available prices and 
converted from US$ to UK£. In the current treatment and guideline strategies, the 
most commonly prescribed generic antihypertensive in each class (indapamide, 
amlodopine, ramipril) and the statin simvastatin were assumed.[35]  Patients on 
antihypertensives were allocated four consultations (mix of GP and practice nurse) 
per year.[43] Two additional visits (one GP, one practice nurse) were included for 
guideline treatment in patients above target blood pressure.  
Analysis 
An incremental cost-utility analysis was undertaken with a threshold of £20,000 per 
QALY taken to indicate cost-effectiveness. Future costs and QALYs were discounted 
at 3.5% per annum.[44] Costs were in UK pounds for 2011/12. Conversion into 
Euros was via the Purchasing Power Parity (PPP) Index for 2012, using a 
conversion rate of £1 to €1.125.[45] A half-cycle correction was applied to costs and 
effectiveness. We explored the impact of changing key parameters in a deterministic 
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sensitivity analysis in a single age-sex stratum (men aged 60-69).  Analysis of impact 
of price involved halving and doubling the price of a ‘polypill’ and reducing the cost to 
£57 (€64) a year, to reflect cost of individual generic agents.[35] The threshold price 
at which a polypill would become cost effective for each sub-group was determined. 
Where available, data were entered into the model as distributions so that a 
probabilistic sensitivity analysis could be undertaken. A log-normal distribution was 
used for all risk reductions and standardised mortality ratios after cardiovascular 
events, a beta distribution for cardiovascular event probabilities, risk of death from 
cardiovascular events and compliance with screening and a gamma distribution for 
acute and long-term costs. A Probabilistic Sensitivity Analysis (PSA) was run with 
10,000 simulations and cost-effectiveness acceptability curves were produced (not 
shown) to provide information on the probability of interventions being cost-effective 
at different cost per QALY thresholds. 
 
Results 
In the base-case analysis, the polypill strategy led to fewer CV events and was cost-
effective over current practice and optimal treatment as per guidelines for men aged 
50-74 and women over the age of 50. Subpopulation results varied from the polypill 
strategy being dominant (i.e. less costly and more effective), to Incremental Cost 
Effectiveness Ratios (ICERs)  up to £18,811 (€21,162) per QALY gained (Tables 2 
and 3). Optimal guideline care was dominant over the polypill for men aged over the 
age of 75 (but with very small differences in costs and QALYs), and most cost-
effective in women aged 40-49.  
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Table 2 Results of the base-case analysis and probabilistic sensitivity analysis: Men 
 
Age 
group Strategy 
Mean 
cost (£) 
Mean 
QALYs  
Mean 
CV 
events 
Incremental 
cost 
Incremental 
QALYs 
ICER (£ 
per QALY 
gained) 
Probability of 
cost-effectiveness 
at £20,000/QALY  
Polypill vs current 
practice 
ICER(£ per QALY 
gained) 
40-49 
Current practice  1,625 7.202 0.0956 0 0 - 0%  
Optimal guideline care 1,634 7.216 0.0822 8 0.014 604 41%  
Polypill  1,878 7.229 0.0683 244 0.014 18,057 59% 9,166 
50-59 
Current practice  2,008 6.740 0.1499 0 0 - 0%  
Optimal guideline care 2,013 6.765 0.1290 5 0.025 182 0%  
Polypill  2,136 6.784 0.1119 123 0.019 6,466 100% 2,897 
60-69 
Optimal guideline care 2,315 6.524 0.1714 0 0 - 0%  
Current practice 2,343 6.477 0.2064 28 -0.047 Dominated 0%  
Polypill  2,386 6.539 0.1592 71 0.015 4,791 100% 698 
70-74 
Optimal guideline care 2,429 5.916 0.1890 0 0 - 9%  
Current practice 2,457 5.853 0.2334 28 -0.063 Dominated 0%  
Polypill  2,459 5.922 0.1861 31 0.006 5,068 91% 33 
 
Optimal guideline care 2,320 4.782 0.1988 0 0 - 69%  
Polypill  2,327 4.781 0.2005 7 -0.001 Dominated 31% Dominant 
75+ Current practice 2,395 4.692 0.2564 68 -0.089 Dominated 0%  
 
 
 
Table 3 Results of the base-case analysis and probabilistic sensitivity analysis: Women 
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Age 
group Strategy 
Mean 
cost (£) 
Mean 
QALYs 
Mean 
CV 
events 
Incremental 
cost 
Incremental 
QALYs 
ICER (£ 
per QALY 
gained) 
Probability of 
cost-
effectiveness at 
£20,000/QALY 
Polypill vs current 
practice 
ICER (£ per QALY 
gained) 
40-49 
Current practice 1,325 7.077 0.0505 0 0 - 0%  
Optimal guideline care 1,343 7.083 0.0446 18 0.006 2,994 94%  
Polypill  1,671 7.093 0.0354 328 0.010 33,585 6% 21,798 
50-59 
Current practice  1,586 6.675 0.0894 0 0 - 0%  
Optimal guideline care 1,599 6.688 0.0770 13 0.013 950 46%  
Polypill  1,841 6.701 0.0644 243 0.013 18,811 54% 9,696 
60-69 
Current practice  1,805 6.513 0.1203 0 0 - 0%  
Optimal guideline care 1,829 6.530 0.1060 23 0.018 1,304 2%  
Polypill  1,994 6.546 0.0928 165 0.015 10,730 98% 5,667 
70-74 
Current practice  1,985 5.982 0.1492 0 0 - 0%  
Optimal guideline care 2,042 6.009 0.1281 57 0.027 2,105 0%  
Polypill  2,097 6.022 0.1170 55 0.013 4,245 100% 2,797 
75+ 
Current practice  1,880 4.733 0.1644 0 0 - 0%  
Optimal guideline care 1,947 4.774 0.1345 66 0.041 1,606 63%  
Polypill  1,967 4.779 0.1303 20 0.005 4,131 37% 1,870 
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The probabilistic sensitivity analysis for all three treatment options showed that the 
polypill had a high probability (over 90%) of being cost-effective at a £20,000 
(€22,500)/QALY threshold for men except for the youngest and oldest sub-groups. 
There was much more uncertainty in the results for  women, with only the 60-69 and 
70-74 sub-groups having a high probability of the polypill being the most cost-
effective option. with considerable uncertainty around the results for those aged 50-
59 (54% probability of being the most cost-effective option at £20,000/QALY). 
(Tables 2 and 3).  
Deterministic sensitivity analyses for men aged 60-69 demonstrated that the superior 
cost effectiveness of a polypill over optimal guideline care over was robust to some 
underlying assumptions made in the model, with some key exceptions. Optimal 
guidelines became the most favourable strategy if take up of a polypill was low, if 
polypill was associated with a small reduction in quality of life, if polypill was less 
effective than assumed, and if the population was restricted to those with 
uncontrolled risk factors only (Table 4). The results were particularly sensitive to the 
cost of the polypill, with dominance achieved by halving the price or further reducing 
to the cost of the individual components.  The superiority of the polypill compared 
with current practice in men aged 60-69 was sensitive to the cost of polypill, but 
robust to changes to the other assumptions (Table 5). Threshold analysis showed 
that the annual price of the polypill would need to be £152 (€171) or less to ensure 
cost-effectiveness at the £20,000 (€22,500)/QALY threshold for all sub-groups when 
compared with guidelines (Table 6).  
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Table 4. Deterministic Sensitivity analysis results (men aged 60-69) for polypill strategy vs 
optimal guideline care 
 Cost difference 
vs. guidelines(£) 
QALY 
difference vs. 
guidelines 
Most CE strategy* and 
ICER (£/QALY) for polypill 
Base case 71 0.015 Polypill (£4,791) 
Sensitivity analysis    
Cost of polypill doubled 342 0.015 Guidelines (£76,849) 
Cost of polypill halved -462 0.015 Polypill dominates 
Cost of polypill reduced to £57/year -640 0.015 Polypill dominates 
Decreased take up of polypill (25% take 
polypill) 
95 -0.029 Guidelines dominates 
Change cost of CV events    
increase by 30% 45 0.015 Polypill (£3,030) 
decrease by 30% 97 0.015 Polypill (£6,553) 
Quality of life reduction with polypill by 
1% 
71 -0.037 Guidelines dominates 
Reduction in polypill effectiveness    
Antihypertensive effect reduced (statin 
effect fixed): 
   
50% 180 -0.004 Guidelines dominates 
25% 126 0.006 Guidelines (£22,500) 
Statins effect reduced (antihypertensive 
effect fixed) by 25% 
95 0.010 Polypill (£9,397) 
Antihypertensive and statin effect 
reduced by 25% 
151 0.001 Guidelines (£228,788) 
Increase costs of achieving optimal 
guideline care‡ 
-582 0.015 Polypill dominates 
Study population restricted to people with 
uncontrolled risk factors at baseline† 
-51 - 0.013 Guidelines (£3,952)** 
Baseline CVD risk reduced by 30% 97 0.011 Polypill (£9,110) 
Alternative time horizon    
20 years 49 0.048 Polypill (£1,011) 
30 years 42 0.078 Polypill (£546) 
Lifetime 40 0.084 Polypill (£473) 
* CE at a £20,000/QALY gained threshold 
** ICER is in the south-west quadrant and polypill is not CE as it is <£20,000/QALY 
† i.e. ≥20% ten year cardiovascular risk and not on a statin, and/or with systolic blood pressure > 140 
mmHg 
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‡ 4 additional (2 GP and 2 practice nurse) consultations per year over usual care, rather than 2 (1 of 
each). 
 
 
 
Table 5. Deterministic Sensitivity analysis results (men aged 60-69) for polypill strategy vs 
current practice 
 Cost difference 
vs. current 
practice 
QALY 
difference vs. 
current 
practice 
Most CE strategy* and ICER 
for polypill 
Base case 43 0.062 Polypill (£698) 
Sensitivity analysis    
Cost of polypill doubled  1,100 0.062 Polypill (£18,045) 
Cost of polypill halved -490 0.062 Polypill dominates 
Cost of polypill reduced £57/year -668 0.062 Polypill dominates 
Decreased take up of polypill (25% take 
polypill) 
67 0.018 Polypill (£3,702) 
Change cost of CV events.    
CV events increase by 30% -67 0.062 Polypill dominates 
CV events decrease by 30% 153 0.062 Polypill (£2.490) 
Quality of life reduction with polypill by 
1% 
43 0.001 Polypill (£4,475) 
Reduction in polypill effectiveness    
Antihypertensive effect reduced (statin 
effect fixed) 
   
50% 152 0.043 Polypill (£3,517) 
25% 98 0.052 Polypill (£1,865) 
    
Statins effect reduced (antihypertensive 
effect fixed) by 25% 
66 0.057 Polypill (£1,169) 
Antihypertensive and statin effect 
reduced by 25% 
122 0.047 Polypill (£2,582) 
Study population restricted to people with 
uncontrolled risk factors at baseline† 
-102 0.081 Polypill dominates 
Baseline CVD risk reduced by 30% 143 0.045 Polypill (£3,206) 
Alternative time horizon    
20 years -5 0.190 Polypill dominates 
30 years 12 0.293 Polypill (£40) 
Lifetime 16 0.315 Polypill (£50) 
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* CE at a £20,000/QALY gained threshold; † i.e. >20% ten year cardiovascular risk and not on a 
statin, and/or with systolic blood pressure > 140 mmHg 
 
 
 
Table 6: Optimal price of polypill  
 
 
Subgroup Annual cost of polypill where the 
polypill is CE vs optimal guideline 
care (£) 
Annual cost of polypill where 
the polypill is CE vs current 
practice (£) 
Male   
40-49 175 215 
50-59 210 285 
60-69 207 361 
70-74 187 408 
75+ 165 542 
Female   
40-49 152 167 
50-59 173 211 
60-69 193 244 
70-74 204 282 
75+ 185 324 
(CE= <£20,000/QALY gained),. Base case price £365.25 
 
 
 
Discussion 
Our base-case analysis suggests that using a polypill is more cost effective than 
usual practice for all age groups over 40 years apart from 40-49 year old women. 
The polypill is also cost-effective compared with optimal implementation of guidelines 
for most age and sex strata. Probabilistic sensitivity analysis showed that the 
superiority of polypill over usual care was very unlikely to be a chance finding, but 
there was more uncertainty over the comparison with optimal implementation of 
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guidelines.  This pattern was reflected in the deterministic sensitivity analysis which 
found that the superiority of polypill over usual care was robust to changing our 
assumptions, but not in comparison to optimal implementation of guidelines,   
Switching to a polypill strategy may be a more cost effective way of improving 
cardiovascular prevention in people on treatment for raised cardiovascular risk than 
current practice or better implementation of guidelines in most patient sub-groups. 
However, this result was highly sensitive to cost of a polypill, take up of this 
treatment and potential effectiveness in reducing CV risk.  At current individual drug 
prices, if a polypill cost £150 (€169) per year (i.e. a cost of 41p (€0.46) per pill), a 
polypill would be more cost effective than achieving optimal guideline care for all 
people over the age of 40 who are on treatment. Given that the costs of prescribing 
the individual components of the polypill are only around £57 (€64) per annum, this 
seems a feasible price not withstanding any technical difficulties of combining 
components in a single pill.   
Previous cost effectiveness analyses have focussed on cost effectiveness of a 
polypill against no treatment, and found that this it is likely to be cost effective for 
primary prevention of high risk individuals in the developing world.[12, 13, 46] 
Trials of using a polypill compared to usual care in people at high risk of 
cardiovascular disease have found better self-reported use of medication in the 
polypill arm,[5,6,7] and in one trial, this was also associated with better control of risk 
factors.[5] None of these trials included any intervention to enhance usual care. 
The results need to be interpreted in the light of certain limitations. In a number of 
respects, the cost effectiveness of a polypill may have been under-estimated. The 
analysis was restricted to higher risk people already on treatment – inclusion of 
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people not on medication would have increased the cost-effectiveness of polypill 
relative to current practice. Potential benefits of improved adherence to a polypill 
were not included.[5]  It was assumed that 100% achievement of guideline targets is 
possible and indeed desirable.[47] However, this has probably not had a significant 
impact on overall results, since blood pressure target trials tend to show that mean 
blood pressure for the study population is below target, even if a substantial 
proportion of individuals have final blood pressure above target.[43,48,49] Thus, the 
impact of blood pressure lowering will have been over-estimated in some patients 
and under-estimated in others in the optimal implementation of guidelines strategy. 
The base-case analysis considered a 10-year time horizon as opposed to a life time 
horizon (which our sensitivity analysis showed tends to favour the polypill). This 
limited time horizon was chosen because of the complexities of estimating changes 
in risk factors (and therefore cardiovascular risk) over time. Finally, the risk of further 
events once someone had an initial cardiovascular event was not modelled, so 
potential benefits of treatments of secondary prevention were ignored. 
Conversely, other assumptions favoured polypill. The separate drugs in the polypill 
were assumed to have additive effects. While one trial did find additive effects,[50] 
others have reported smaller combined effects.[3] The polypill was assumed to have 
no adverse effects on quality of life – sensitivity analysis showed that a small shift in 
this assumption would favour current practice. However, there is no empirical 
evidence of differences in quality of life between people on the polypill or usual 
care.[5]  Optimal guideline care was based on guidelines in force in the UK up until 
2014. Recent NICE guidelines have lowered the 10 year risk threshold for statin 
treatment from 20% to 10%.[34]  This would result in a higher proportion of the study 
population being treated with statins in the optimal guideline implementation. This 
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would have little effect on older age groups (see Table 1), but would result in 
increased effectiveness (and cost) of optimal guideline care in younger age groups. 
Finally, there are several other potential formulations of a polypill, which might have 
different effects on cardiovascular risk factors.[3]    
Conclusions 
This analysis suggests that a polypill strategy may be a cost effective means to 
improve primary prevention in most people aged 50 and over with high 
cardiovascular risk on treatment, as long as the cost of a polypill is sufficiently low. If 
the cost of a polypill is lower than £150 (€169) per year, then this approach becomes 
cost effective for all sub-groups.  However, despite the growing evidence base of the 
effectiveness of polypills,[3,5] such combinations are not yet generally available.  
This perhaps in part reflects reluctance of pharmaceutical companies to invest in 
multi-component pills and the hurdles posed by regulatory approval.[51] At the right 
price, a polypill strategy could be the most cost effective way of ensuring optimal 
cardiovascular risk reduction in people who are on treatment with antihypertensives 
or lipid lowering agents to lower their cardiovascular risk.   
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